There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

Background Single-agent nivolumab showed durable responses, manageable safety, and
promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-
related death worldwide. The treatment of HCC remains challenging and is largely …

Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

Sorafenib: sorafenib has only been evaluated in the firstline setting. Phase IV/observational
studies have not revealed new safety signals in patients with Childe Pugh B cirrhosis 4 [I, A; …

Primary liver cancer, the major histology of which is hepatocellular carcinoma (HCC), is the
second leading cause of cancer death worldwide. We comprehensively examined recent …